The resurgence of covalent drugs
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Covalent inhibitors, also known as irreversible inhibitors, are a class of inhibitors that bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity, compared to that of non-covalent inhibitors, which achieve binding and inhibition of target proteins through non-covalent interactions such as hydrogen bond and van”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [30]
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“The initial binding step (K1) and the subsequent chemical reaction step (kinact) are two important factors determining the selectivity of covalent inhibitors (Fig. 7) [37].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“An irreversible mechanism of action also helps to mitigate against competition by high intracellular concentrations of AT”
BackgroundLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Cited by
Items 601–700 of 1,001
Udompholkul, P., Garza-Granados, A., Alboreggia, G., Baggio, C., McGuire, J. R., Pegan, S. D., & Pellecchia, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00467 · Cited by 40
Uesugi, S., Fujisawa, N., Yoshida, J., Watanabe, M., Dan, S., Yamori, T., Shiono, Y., & Kimura, K. (2015) · The Journal of Antibiotics · doi:10.1038/ja.2015.103 · Cited by 38
Fueller, F., Jehle, B., Putzker, K., Lewis, J., & Krauth‐Siegel, R. L. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.338285 · Cited by 35
Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines
Temburnikar, K. W., Zimmermann, S. C., Kim, N. T., Ross, C. R., Gelbmann, C. B., Salomon, C. E., Wilson, G. M., Balzarini, J. M., & Seley‐Radtke, K. L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.033 · Cited by 37
Huang, Y., Xu, Y., Song, R., Ni, S., Liu, J., Xu, Y., Ren, Y., Rao, L., Wang, Y., Wei, L., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00699 · Cited by 33
Tackling assay interference associated with small molecules
Tan, L., Hirte, S., Palmacci, V., Stork, C., & Kirchmair, J. (2024) · Nature Reviews Chemistry · doi:10.1038/s41570-024-00593-3 · Cited by 39
“…to chemical reactivity can be addressed with time-resolved measurements (covalent binders commonly show an increasing inhibitory effect over time 193–196 ), ‘jump-dilution experiments’ (involving the drastic dilution of the test compound with the target into a substrate-rich environment, by…”
Zhang, K., Zhang, Y., Li, M., Pannecouque, C. C., Clercq, E. D., Wang, S., & Chen, F. (2024) · Medicinal Research Reviews · doi:10.1002/med.22080 · Cited by 35
Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions
Sharma, A. M., & Uetrecht, J. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.848214 · Cited by 36
Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors
Dittus, L., Werner, T., Muelbaier, M., & Bantscheff, M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00617 · Cited by 34
Lü, H., Iuliano, J. N., & Tonge, P. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.002 · Cited by 39
Arylfluorsulfat‐basierte Elektrophile für die kovalente Proteinmarkierung
Martín‐Gago, P., & Olsen, C. A. (2018) · Angewandte Chemie · doi:10.1002/ange.201806037 · Cited by 35
Katsuya, K., Hori, Y., Oikawa, D., Yamamoto, T., Umetani, K., Urashima, T., Kinoshita, T., Ayukawa, K., Tokunaga, F., & Tamaru, M. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218793066 · Cited by 34
Discovery of novel pyrazole derivatives as potential anticancer agents in MCL
Ran, F., Liu, Y., Zhang, D., Liu, M., & Zhao, G. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.005 · Cited by 34
Periplasmic Targets for the Development of Effective Antimicrobials against Gram-Negative Bacteria
Pandeya, A., Ojo, I., Alegun, O., & Wei, Y. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00384 · Cited by 39
Covalent Inhibition of Bacterial Urease by Bifunctional Catechol-Based Phosphonates and Phosphinates
Pagoni, A., Grabowiecka, A., Tabor, W., Mucha, A., Vassiliou, S., & Berlicki, Ł. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01143 · Cited by 34
Covalent Proteomimetic Inhibitor of the Bacterial FtsQB Divisome Complex
Paulussen, F. M., Schouten, G. K., Moertl, C., Verheul, J., Hoekstra, I., Koningstein, G. M., Hutchins, G. H., Alkir, A., Luirink, R. A., Geerke, D. P., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c06304 · Cited by 32
Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site
Murarka, S., Martín‐Gago, P., Schultz‐Fademrecht, C., Al Saabi, A., Baumann, M., Fansa, E. K., Ismail, S., Nussbaumer, P., Wittinghofer, A., & Waldmann, H. (2017) · Chemistry – A European Journal · doi:10.1002/chem.201603222 · Cited by 32
The proximity-enabled sulfur fluoride exchange reaction in the protein context
Yu, B., Cao, L., Li, S., Klauser, P. C., & Wang, L. (2023) · Chemical Science · doi:10.1039/d3sc01921g · Cited by 33
Yamane, D., Tetsukawa, R., Zenmyo, N., Tabata, K., Yoshida, Y., Matsunaga, N., Shindo, N., & Ojida, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00737 · Cited by 35
Dalton, S. E., Pietro, O. D., & Hennessy, E. T. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02661 · Cited by 38
Tomásio, S. M., Harding, H. P., Ron, D., Cross, B. C. S., & Bond, P. J. (2013) · Molecular BioSystems · doi:10.1039/c3mb70234k · Cited by 39
Erlanson, D. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00294 · Cited by 33
Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile
Bošković, Ž., Kemp, M. M., Freedy, A. M., Viswanathan, V. S., Pop, M. S., Fuller, J. H., Martínez, N. M., Figueroa-Lazú, S., Hong, J. A., Lewis, T. A., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00012 · Cited by 35
Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview
Guedes, R. A., Serra, P., Salvador, J. A. R., & Guedes, R. C. (2016) · Molecules · doi:10.3390/molecules21070927 · Cited by 33
Elwood, F., Witter, D. J., Piesvaux, J., Kraybill, B. C., Bays, N. W., Alpert, C., Goldenblatt, P., Qu, Y., Ivanovska, I. L., Lee, H., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239723 · Cited by 33
Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase
Harris, C. M., Foley, S. E., Goedken, E. R., Michalak, M., Murdock, S., & Wilson, N. S. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218787445 · Cited by 36
Pharmacological Modulators of Tau Aggregation and Spreading
Dominguez‐Meijide, A., Vasili, E., & Outeiro, T. F. (2020) · Brain Sciences · doi:10.3390/brainsci10110858 · Cited by 41
“…may interact non-specifically with other proteins, causing o ff -target e ff ects [163] and, therefore, this type of substances has long been avoided, due to the fear of unspecific modifications and the fear that the haptenization of modified proteins might lead to an immune response [200,201].”
BackgroundDevelopment of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor
Serafim, R. A. M., Santiago, A. D. S., Schwalm, M. P., Hu, Z., dos Reis, C. V., Takarada, J. E., Mezzomo, P., Massirer, K. B., Kudolo, M., Gerstenecker, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01165 · Cited by 36
Zhang, Q., Chen, X., Cao, J., Yang, W., Wan, G., Feng, Q., Zhou, S., Yang, H., Wang, N., Liu, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01370 · Cited by 36
Rational design of reversible and irreversible cysteine sulfenic acid-targeted linear C-nucleophiles
Gupta, V., & Carroll, K. S. (2016) · Chemical Communications · doi:10.1039/c6cc00228e · Cited by 33
Dietary Acetylenic Oxylipin Falcarinol Differentially Modulates GABAA Receptors
Czyzewska, M. M., Chrobok, Ł., Kania, A., Jatczak-Śliwa, M., Pollastro, F., Appendino, G., & Mozrzymas, J. W. (2014) · Journal of Natural Products · doi:10.1021/np500615j · Cited by 33
Target identification of covalently binding drugs by activity-based protein profiling (ABPP)
Pichler, C. M., Krysiak, J. M., & Breinbauer, R. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.050 · Cited by 36
de Araujo, A. D., Lim, J., Good, A. C., Skerlj, R. T., & Fairlie, D. P. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00395 · Cited by 36
Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins
Liu, X., Feng, D., Zheng, M., Cui, Y., & Zhong, D. (2020) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2020.07.002 · Cited by 32
Abuhammad, A., Fullam, E., Lowe, E. D., Staunton, D., Kawamura, A., Westwood, I. M., Bhakta, S., Garner, A. C., Wilson, D., Seden, P. T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052790 · Cited by 34
Characterization of Covalent-Reversible EGFR Inhibitors
Smith, S. P., Keul, M., Engel, J., Basu, D., Eppmann, S., & Rauh, D. (2017) · ACS Omega · doi:10.1021/acsomega.7b00157 · Cited by 35
A Bifunctional Fluorogenic Rhodamine Probe for Proximity‐Induced Bioorthogonal Chemistry
Werther, P., Möhler, J. S., & Wombacher, R. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201703607 · Cited by 34
Chen, D., Guo, D., Yan, Z., & Zhao, Y. (2017) · MedChemComm · doi:10.1039/c7md00571g · Cited by 32
Yoshizawa, M., Itoh, T., Hori, T., Kato, A., Anami, Y., Yoshimoto, N., & Yamamoto, K. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00774 · Cited by 32
Chen, Z., Mori, W., Fu, H., Schafroth, M. A., Hatori, A., Shao, T., Zhang, G., Van, R. S., Zhang, Y., Hu, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00936 · Cited by 32
WIDOCK: a reactive docking protocol for virtual screening of covalent inhibitors
Scarpino, A., Petri, L., Knez, D., Imre, T., Ábrányi‐Balogh, P., Ferenczy, G. G., Gobec, S., & Keserű, G. M. (2021) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00371-5 · Cited by 36
“1 3 Indeed, the non-covalent interactions formed in the pocket are important to place the warhead in the right position and orientation with respect to the protein nucleophile in order to allow for the chemical reaction [2].”
BackgroundXia, Z., Huang, R., Zhou, X., Chai, Y., Chen, H., Ma, L., Yu, Q., Li, Y., Li, W., & He, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113711 · Cited by 36
Lai, J.-H., Yang, J.-T., Chern, J., Chen, T.-L., Wu, W., Liao, J., Tsai, S., Liang, S., Chou, C., & Wu, S. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.051052 · Cited by 32
LC–MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma
Kiesel, B. F., Parise, R. A., Wong, A., Keyvanjah, K., Jacobs, S. A., & Beumer, J. H. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.11.035 · Cited by 32
Engel, J., Smith, S. P., Lategahn, J., Tumbrink, H. L., Goebel, L., Becker, C., Hennes, E., Keul, M., Unger, A., Müller, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00515 · Cited by 36
Clapper, J. R., Henry, C. L., Niphakis, M. J., Knize, A., Coppola, A. R., Simon, G. M., Ngo, N., Herbst-Graham, R. A., Herbst, D. M., Reed, A., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252296 · Cited by 34
“Covalent inhibition can be an attractive mechanism for enzyme inactivation because high biochemical efficiency and an extended duration of target engagement, compared with the PK profile, can often be achieved (Johnson et al., 2010; Singh et al., 2011).”
BackgroundA practical guide for the assay-dependent characterisation of irreversible inhibitors
Mader, L. K., Borean, J. E., & Keillor, J. W. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00707g · Cited by 37
CovalentDock Cloud: a web server for automated covalent docking
Ouyang, X., Zhou, S., Ge, Z., Li, R., & Kwoh, C. K. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt406 · Cited by 32
Hernández‐Prat, A., Rodríguez‐Vida, A., Juanpere-Rodero, N., Arpí, O., Menéndez, S., Soria‐Jiménez, L., Martínez, A., Iarchouk, N., Rojo, F., Albanell, J., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0923 · Cited by 31
A Liquid Chromatography/Mass Spectrometry Method for Screening Disulfide Tethering Fragments
Hallenbeck, K. K., Davies, J. L., Merron, C., Ogden, P., Sijbesma, E., Ottmann, C., Renslo, A. R., Wilson, C., & Arkin, M. R. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217732072 · Cited by 35
Gambini, L., Udompholkul, P., Salem, A. F., Baggio, C., & Pellecchia, M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000355 · Cited by 32
Suto, N., Kamoshita, S., Hosoya, S., & Sakurai, K. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202104347 · Cited by 32
Tunable heteroaromatic azoline thioethers (HATs) for cysteine profiling
Tang, K. C., Maddox, S. M., Backus, K. M., & Raj, M. (2021) · Chemical Science · doi:10.1039/d1sc04139h · Cited by 31
Protein Electric Fields Enable Faster and Longer-Lasting Covalent Inhibition of β-Lactamases
(2022) · doi:10.1021/jacs.2c09876 · Cited by 31
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S N Ar Electrophiles
Schwarz, M., Kurkunov, M., Wittlinger, F., Rudalska, R., Wang, G., Schwalm, M. P., Rasch, A., Wagner, B., Laufer, S., Knapp, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02483 · Cited by 32
Duan, D., Guo, X., Tian, J., Li, M., Jin, X., Wang, Z., Wang, L., Yan, Y., Xiao, J., Song, P., et al. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111137 · Cited by 30
Boron enabled bioconjugation chemistries
Zheng, M., Kong, L., & Gao, J. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00750f · Cited by 34
Pejchal, V., Štěpánková, Š., Pejchalová, M., Královec, K., Havelek, R., Růžičková, Z., Ajani, H., Lo, R., & Lepšı́k, M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.02.033 · Cited by 34
Böhm, M.-E., Krey, V. M., Jeßberger, N., Frenzel, E., & Scherer, S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00768 · Cited by 30
Irreversible Enzyme Inhibition Kinetics and Drug–Drug Interactions
Mohutsky, M. A., & Hall, S. D. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-758-7_5 · Cited by 30
Federspiel, J. D., Codreanu, S. G., Goyal, S., Albertolle, M. E., Lowe, E., Teague, J., Wong, H. L., Guengerich, F. P., & Liebler, D. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.059709 · Cited by 30
cBinderDB: a covalent binding agent database
Du, J., Yan, X., Liu, Z., Cui, L., Ding, P., Tan, X., Li, X., Zhou, H., Gu, Q., & Xu, J. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw801 · Cited by 30
Field, J., Northcote, P. T., Paterson, I., Altmann, K., Díaz, J. F., & Miller, J. H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050971 · Cited by 29
Schnute, M. E., Benoit, S., Buchler, I. P., Caspers, N. L., Grapperhaus, M. L., Han, S., Hotchandani, R., Huang, N., Hughes, R. O., Juba, B. M., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00461 · Cited by 31
Zhang, C., Pei, H., He, J., Zhu, J., Li, W., Niu, T., Xiang, M., & Chen, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.077 · Cited by 30
Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery
Bian, Y., Jun, J. J., Cuyler, J., & Xie, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112690 · Cited by 33
Covalent labeling of a chromatin reader domain using proximity-reactive cyclic peptides
Zhang, M. Y., Yang, H., Ortiz, G., Trnka, M. J., Petronikolou, N., Burlingame, A. L., DeGrado, W. F., & Fujimori, D. G. (2022) · Chemical Science · doi:10.1039/d2sc00555g · Cited by 34
Jain, P., Satija, J., & Sudandiradoss, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-35192-7 · Cited by 36
“Andrographolide is a natural electrophilic covalent inhibitor, derived from the terpenoid pathway and privileged with the structural features which are necessary for binding with multiple targets 24–26 .”
BackgroundGao, Q., Mechin, I., Kothari, N. H., Guo, Z., Deng, G., Haas, K., McManus, J., Hoffmann, D., Wang, A., Wiederschain, D., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.473348 · Cited by 30
Targeted covalent inhibition of O -GlcNAc transferase in cells
Worth, M., Hu, C., Li, H., Fan, D., Estevez, A., Zhu, D., Wang, A., & Jiang, J. (2019) · Chemical Communications · doi:10.1039/c9cc04560k · Cited by 31
Kenakin, T. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00958-9 · Cited by 35
CryptoBench: cryptic protein–ligand binding sites dataset and benchmark
Škrhák, V., Novotný, M., Feidakis, C. P., Krivák, R., & Hoksza, D. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae745 · Cited by 44
“Further, we have decided to keep even ligands that are co-valently attached as they have proven to be relevant and successful in drug design (Singh et al. 2011).”
Rational Design Strategies in DNA‐Encoded Libraries for Drug Discovery
Wang, X., Li, L., Shen, X., & Lu, X. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202511839 · Cited by 33
Neratinib (HKI-272) in the Treatment of Breast Cancer
López‐Tarruella, S., Jerez, Y., Márquez‐Rodas, I., & Martín, M. (2012) · Future Oncology · doi:10.2217/fon.12.66 · Cited by 29
First-in-class small molecule potentiators of cancer virotherapy
Dornan, M. H., Krishnan, R., Macklin, A. M., Selman, M., El-Sayes, N., Son, H. H., Davis, C., Chen, A., Keillor, K., Le, P. J., et al. (2016) · Scientific Reports · doi:10.1038/srep26786 · Cited by 32
Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches
Zhang, Y., Zhang, D., Tian, H.-Z., Jiao, Y., Shi, Z., Ran, T., Liu, H., Lü, S., Xu, A., Qiao, X., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00302 · Cited by 35
Carramiñana, V., de Retana, A. M. O., del Burgo, A. V., Santos, J. M. D. L., & Palácios, F. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.002 · Cited by 29
Carramiñana, V., de Retana, A. M. O., Santos, J. M. D. L., & Palácios, F. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111771 · Cited by 30
Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment
Ceramella, J., Iacopetta, D., Barbarossa, A., Caruso, A., Grande, F., Bonomo, M. G., Mariconda, A., Longo, P., Saturnino, C., & Sinicropi, M. S. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200117144701 · Cited by 30
The complexity of T cell–mediated penicillin hypersensitivity reactions
Goh, S. J. R., Tuomisto, J. E. E., Purcell, A. W., Mifsud, N. A., & Illing, P. T. (2020) · Allergy · doi:10.1111/all.14355 · Cited by 33
Anaphylaxis to drugs: Overcoming mast cell unresponsiveness by fake antigens
Pichler, W. J. (2020) · Allergy · doi:10.1111/all.14554 · Cited by 30
“Of note, the drug-protein complexes or adducts based on non-covalent or covalent bindings have a very similar “appearance”, as the location of binding and the orientation of the drug versus protein may be the same in non-covalent and covalent bindings (14).”
BackgroundSingh, N., & Villoutreix, B. O. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.059 · Cited by 27
“Also, covalent binders [98] can be of interest, definitively to act on viral enzymes [99] but also to block PPIs as seen in the field of cancer [100].”
Bonatto, V., Shamim, A., Rocho, F. D. R., Leitão, A., Luque, F. J., Lameira, J., & Montanari, C. A. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00515 · Cited by 32
Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein
Udompholkul, P., Baggio, C., Gambini, L., Alboreggia, G., & Pellecchia, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01459 · Cited by 31
Targeted Covalent Inhibition of Telomerase
Betori, R. C., Liu, Y., Wu, D., Mishra, R., Cohen, S., Kron, S. J., & Scheidt, K. A. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b00945 · Cited by 30
Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal Chemistry
Sweis, R. F. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00183 · Cited by 29
Polepally, P. R., Huben, K., Vardy, E., Setola, V., Mosier, P. D., Roth, B. L., & Zjawiony, J. K. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.077 · Cited by 28
A Redox Economical Synthesis of Bioactive 6,12-Guaianolides
Wen, B., Hexum, J. K., Widen, J. C., Harki, D. A., & Brummond, K. M. (2013) · Organic Letters · doi:10.1021/ol400904y · Cited by 32
Targeting peroxiredoxins against leukemia
Liu, C., Zhou, H., Yin, Q., Wu, Y., & Chen, G. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.06.013 · Cited by 29
Reactive Electrophiles and Metabolic Activation
Obach, R. S., & Kalgutkar, A. S. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00115-9 · Cited by 30
Zhang, L., & Mager, D. E. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9445-x · Cited by 28
Activation of Inflammasomes by Agents Causing Idiosyncratic Skin Reactions: A Possible Biomarker
Weston, J. K., & Uetrecht, J. (2014) · Chemical Research in Toxicology · doi:10.1021/tx5001333 · Cited by 28
The Antiviral Potential of Host Protease Inhibitors
Steinmetzer, T., & Hardes, K. (2018) · Springer eBooks · doi:10.1007/978-3-319-75474-1_11 · Cited by 28
“Another strategy is the design of covalent inhibitors (Singh et al.”
BackgroundEvaluating QM/MM Free Energy Surfaces for Ranking Cysteine Protease Covalent Inhibitors
da Costa, C. H. S., Bonatto, V., dos Santos, A. M., Lameira, J., Leitão, A., & Montanari, C. A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00847 · Cited by 26
Khalaf, H. S., Naglah, A. M., Al-Omar, M. A., Moustafa, G. O., Awad, H. M., & Bakheit, A. H. H. (2020) · Molecules · doi:10.3390/molecules25163589 · Cited by 43
“Almost 30% of the drugs marketed target enzymes that are reacted via covalent addition, therefore targeted covalent inhibitors (TCI) are becoming increasingly significant [16].”
BackgroundTabuchi, Y., Yang, J., & Taki, M. (2021) · Chemical Communications · doi:10.1039/d0cc08109d · Cited by 31
Catalano, C., Mughram, M. H. A., Guo, Y., & Kellogg, G. E. (2021) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2021.09.002 · Cited by 30
“Also, cysteine is an especially well-known target for covalent (irreversible) inhibition (Singh et al., 2011; Hallenbeck et al., 2017; Long and Aye, 2017; Heppner, 2021).”
BackgroundFan, Y., Si, H., Zhang, Z., Zhong, L., Sun, H., Zhu, C., Yin, Z., Li, H., Tang, G., Yao, S. Q., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02024 · Cited by 29
Wang, Y., Min, J., Deng, X., Feng, T., Hu, H., Guo, X., Cheng, Y., Xie, B., Yang, Y., Chen, C.-C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.005 · Cited by 28
“By covalent targeting, high binding affinity and selectivity were obtained 22 e 24 .”
BackgroundFakhouri, L. I., El‐Elimat, T., Hurst, D. P., Reggio, P. H., Pearce, C. J., Oberlies, N. H., & Croatt, M. P. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.09.037 · Cited by 28
Metadata
- Authors
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A.
- Affiliations
- University of Washington (US)
- Boston University (US)
- Corresponding author
- Singh, Juswinder
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 307-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2010993054
- Cited by
- 1,873
- References
- 71
- Citations by year
- 2026: 136 · 2025: 150 · 2024: 148 · 2023: 137 · 2022: 145 · 2021: 162 · 2020: 152 · 2019: 98 · 2018: 132 · 2017: 125 · 2016: 141 · 2015: 96 · 2014: 81 · 2013: 85 · 2012: 66
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM094551)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- covalent inhibitors, drug safety, covalent drug design, targeted covalent inhibitors
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Structure-Activity Relationship, Drug Design, Drug Delivery Systems, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.